Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  14.00 3.54% 410.00 400.00 402.00 406.00 388.00 388.00 45,344 16:35:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -20.5 -26.2 - 320

Silence Therapeutics Share Discussion Threads

Showing 50201 to 50224 of 50950 messages
Chat Pages: Latest  2014  2013  2012  2011  2010  2009  2008  2007  2006  2005  2004  2003  Older
DateSubjectAuthorDiscuss
11/9/2017
07:50
some additional reading and phone calling.
tsmith2
08/9/2017
22:22
Overdone? You were saying sell on Thursday, make up your mind jockey
rogen83
08/9/2017
12:38
Fall overdone?
tsmith2
08/9/2017
10:43
hTTps://www.youtube.com/watch?v=ZNt5FnMK2sM
buywell3
08/9/2017
10:38
That's biotech for you.
1gw
08/9/2017
10:33
Looked good for a while there. Hopefully will again soon
volsung
07/9/2017
16:59
Crazy reaction today - Arrowhead up 10%
rogen83
07/9/2017
16:11
Meanwhile Arrowhead up another 10%...
1gw
07/9/2017
15:24
Well the focus is Givosiran but I think they said a bit earlier that one advantage for rolling out Givosiran will be that Patisiran will already be out there, so they will already have the infrastructure in place. I've bought back some more just now on the basis of the Givosiran presentation on top of the sense I get that they expect the Fitusiran program just to have been delayed a few months. They're aiming for US approval of Givosiran in early-mid 2019 if data is positive (after interim analysis in mid-2018). It doesn't sound like there are all that many patients that would benefit but the cost of treating them at present is enormous according to some numbers just quoted.
1gw
07/9/2017
15:10
Anything about Patisiran 1gw?
callumross
07/9/2017
14:58
Alnylam currently webcasting their Givosiran RNAi Roundtable presentation. Not the most exciting of presentations for a non-techie such as myself but I think the gist of it is that they've had some encouraging results - and indeed the scientist presenting it sounds almost excited at the moment. I presume Silence's patent lawyers and scientists are watching with interest.
1gw
07/9/2017
13:36
It has at least put the brakes on the share price. Who knows - if there's any truth to the suggestions that Alnylam might look to settle the patent dispute by taking over Silence then now might be a good time to strike. Certainly it seemed to me from the Alnylam call that Alnylam see the Fitusiran death as tragic but by no means an end to their hopes for the drug.
1gw
07/9/2017
12:37
Hopefully settling down a bit now 1gw
volsung
07/9/2017
12:33
Same experience volsung. Was hoping to get it in the 150's but ended up paying 168. According to the presentation (slide 9), Alnylam are aiming "to resume dosing in fitusiran studies as soon as possible, potentially in late 2017, upon agreement with global regulatory authorities, and with appropriate protocol amendments for enhanced patient safety monitoring" hTtp://files.shareholder.com/downloads/ABEA-430HSO/5140862297x0x955997/478887AC-CAA1-4AE0-B243-854121D59851/Fitu-Givo_CC-slides_FINAL_090717.pdf
1gw
07/9/2017
12:26
Sold a third of mine just after the interims. Those were the ones I bought back at 169p. Had I waited a couple of seconds might have got them 10p cheaper!
volsung
07/9/2017
12:22
I've just bought back the ones I sold yesterday. Alnylam webcast is currently in progress for anyone interested. They've just started on the Q&A.
1gw
07/9/2017
12:22
Hopefully. I'm sure the impressive rise over the past few months wasn't just due to fitusiran. name of the game with pharma though...volatility
volsung
07/9/2017
12:18
As I said , seems overdone.
rogen83
07/9/2017
12:17
Not the best investment. oh well
volsung
07/9/2017
12:12
Looks to me like bad news on fitusiran but good news on givosiran, both of which are mentioned in the Silence 3rd July rns. hTtp://investors.alnylam.com/releasedetail.cfm?ReleaseID=1039464
1gw
07/9/2017
12:07
Never look a gift horse in the mouth. I've bought another £8k worth
volsung
07/9/2017
12:07
Fitusiran..sell
tsmith2
07/9/2017
11:22
SLN getting knocked by an update from Alynlam but it's not the update on Patisiran so seems a bit harsh
rogen83
06/9/2017
12:21
"CALLUMROSS"you are in theory correct but this never actually happens in practice.
dp1umb
Chat Pages: Latest  2014  2013  2012  2011  2010  2009  2008  2007  2006  2005  2004  2003  Older
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191120 05:24:36